abstract |
The use of Pgp inhibitors, in particular second and third generation resistance modifying agents in the preparation of medicaments for the treatment of cancer and in a method of treating cancer in human or non-human animal subjects, wherein said cancerous cells are multi-drug resistant (MDR) and the MDR phenomenon is dependent upon over-expression of Pgp. |